Skip to main content

Table 1 Patient demographics and clinical characteristics

From: A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma

Characteristic

Age, Mean, y (range)

55 (30–64)

Sex

 Male, No. (%)

10 (59)

 Female, No. (%)

7 (41)

Stage, No. (%)

 Unresectable III

8 (47)

 M1a

2 (12)

 M1b

1 (6)

 M1c

6 (35)

ECOG PS, No. (%)

 0

15 (88)

 1

2 (12)

LDH, No. (%)

 Normal

12 (71)

 >ULN

5 (29)

Mutation status

 BRAF V600E/K

12 (71)

 C-KIT

1 (6)

 NRAS Q61R

1 (6)

 WT

3 (18)

  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group performance status, LDH lactate dehydrogenase, No number, ULN upper limit of normal
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us